United States
Based in Boston, Val has written for many of the world's top news agencies, including MarketWatch, The Wall Street Journal, Dow Jones Newswires, Reuters, and Business Insider. Her work has also appeared in the Boston Business Journal, MT Newswires, BioCentury, ZDNet, MediaPost, GoodRx, and MassDevice.com.
How Can I Show Proof of Vaccination for COVID-19?
Li-Cycle Seen as Pure Play in Emerging Battery Recycling Space
Tesla Moves Headquarters to Texas, Ramps Up Production in California
COVID-19 is a cunning disease that has taken many medical experts by surprise. The COVID-19 virus acts differently than other viral pathogens, capable of jumping from one person to the next before a patient shows symptoms. Like the common cold, it can cause a loss of taste and smell, but unlike the cold, it does this without much nasal congestion.
Lung cancer is the leading cause of cancer death for women worldwide. And it can be particularly deadly for Asian females. Women of Asian descent are at significantly higher risk of developing a type of lung cancer associated with a genetic mutation of the epidermal growth factor receptor (EGFR) protein.
BOSTON (MarketWatch) - By anyone's standard, Michael Bonney's first few days at Cubist Pharmaceuticals Inc. didn't go well. It was 2002. Bonney had just come on board from Biogen, where he had helped launch one of the most successful drugs in biotechnology history, Avonex.
The medtech industry is getting serious about cybersecurity. At a recent seminar held by the Mass. Medical Device Industry Council (MassMEDIC), medical device executives, regulators and security experts discussed which systems and devices were most vulnerable to malicious hacking and what could be done to stop it.
BOSTON (MarketWatch) - After years of being swatted about like ping-pong balls, are stem-cell stocks now worth a second look? Perhaps no other medical subsector has had to endure as much volatility as the fledgling stem-cell space, where even the most obscure story on regenerative science can produce double-digit stock moves, thanks in part to the companies' diminutive stock floats.
Aethlon Medical (OTC: AEMD) plans to begin U.S. clinical trials for its Hemopurifier device by the end of the year for the treatment of hepatitis C and hopes to eventually expand testing to cover such deadly pathogens as Ebola, Aethlon CEO Jim Joyce told MassDevice.com.
Fake drugs are proliferating online--here's how to stay safe
BOSTON (MarketWatch) -- Wall Street is betting that three new experimental diet drugs could be huge commercial hits in a super-sizing America, but how comfortable would doctors be with prescribing the pills? Clinical studies have shown all three -- Vivus Inc.'s Qnexa, Orexigen Therapeutics' OREX Contrave and Arena Pharmaceuticals' lorcaserin-- can be effective in helping obese patients lose at least 5% of their body weight.
ASK About Lung Cancer's founder, Bob Mann, talks about his wife Liz's diagnosis of EGFR-mutated lung cancer, how Asian women are at higher risk for the mutation, and how early detection and advances in drug therapy are helping to extend lives.
Lung cancer can be a killer--even if you've never smoked. ASK About Lung Cancer is dedicated to Awareness, Screening and Knowledge of EGFR-mutated non-small cell lung cancer, a type of lung cancer associated with a genetic mutation of the EGFR protein.
BOSTON (MarketWatch) - Pandemic. The word alone evokes images of societal chaos. But is that what we're really in for this fall, when the world faces its first official pandemic flu season since 1968? Not exactly, say public health experts.
BOSTON (MarketWatch) -- Here are answers to a few of the most frequently asked questions about avian flu and the impact of a possible pandemic in the near future. What exactly is 'avian flu'? The avian flu is a strain of influenza that has decimated bird populations, particularly in Asia.
BOSTON - The days of market exclusivity could soon come to an end for the biotech industry if Congress moves forward with plans to allow generic biologics on the U.S. market. Because of their eye-popping price tags, pressure to rein in the cost of biologics has been mounting on Capitol Hill for some time.